Boule Diagnostics secured major tender in India

A major tender has been secured in India, including a large number of instruments as well as reagents and controls. This complex tender process has been ongoing for an extended period of time and has been brought to a successful conclusion for Boule by our local country manager in close collaboration with one of our key distributors. Deliveries of 650 instruments are expected to take place during the third and fourth quarter of 2018.

Winning this tender further strengthens Boule´s position in the Indian market and can lead to further instrument sales in addition to the ongoing reagent and control sales supporting the installed base.

For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 70-558 51 05
Christina Rubenhag, CFO Boule Diagnostics AB, phone +46 70-546 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA and Mexico. The company’s products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. 

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.15 CET on August 7, 2018.


  • Subscribe to our news